CoChat

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Open access
Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J. · 2020 · Antimicrobial Agents and Chemotherapy
Cited by 47

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β- d -glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive pulmonary aspergillosis (IPA). The combination of ibrexafungerp and isavuconazole in in vitro studies resulted in additive and synergistic interactions against Aspergillus spp.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02429-19

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 22

  1. 10.1136/thoraxjnl-2014-206291 · DOI · Paper page
  2. 10.1080/13693780902718339 · DOI
  3. 10.1097/MPH.0b013e3181acd956 · DOI
  4. 10.1053/j.seminhematol.2009.03.008 · DOI
  5. 10.1128/AAC.01510-19 · DOI · Paper page
  6. 10.1080/14787210.2018.1536546 · DOI
  7. 10.1128/AAC.02145-13 · DOI · Paper page
  8. 10.1093/jac/dkx033 · DOI
  9. 10.1093/jac/dks466 · DOI · Paper page
  10. 10.1128/AAC.04445-14 · DOI · Paper page
  11. 10.1128/AAC.02068-16 · DOI · Paper page
  12. 10.1128/AAC.00585-18 · DOI
  13. 10.1093/cid/cix198 · DOI
  14. 10.1111/myc.12769 · DOI
  15. Petraitis V, Kavaliauskas P, Planciuniene R, Virgailis M, Petraitiene R, Barat S, Borroto-Esoda K, Angulo D, Walsh TJ. 2018. In vitro activity of SCY-078 in combination with isavuconazole or amphotericin B against medically important moulds, abstr 498. ASM Microbe 2018. ASM, Atlanta, GA.
  16. 10.1086/375420 · DOI · Paper page
  17. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved Standard—2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
  18. 10.1128/aac.47.1.106-117.2003 · DOI · Paper page
  19. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
  20. Walsh TJ, Bacher J, Pizzo PA. 1988. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467–471.
  21. 10.1128/AAC.45.3.857-869.2001 · DOI · Paper page
  22. 10.1128/AAC.00674-08 · DOI

Cited by

See all 47

Metadata

Authors
Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., Angulo, D., & Walsh, T. J.
Venue
Antimicrobial Agents and Chemotherapy
Published
2020-05-21
Volume
64
Issue
6
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W3011590223
Cited by
47
References
8
FWCI
0.69
Type
journal article
Language
en
Open access
green
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Funders
  • Scynexis, Inc.
  • Save Our Sick Kids Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. https://app.cochat.ai/papers/10.1128/aac.02429-19
The paper
Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., Angulo, D., & Walsh, T. J. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02429-19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.